sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (Nizoral) levodopa lithium muscle relaxants birth control pills sleeping pills thyroid medications
|
antidepressants
|
antihistamines
|
NONE
|
Fluoxetine_ddi.xml
|
DDI-DrugBank.d482.s14
|
DDI-DrugBank.d482.s14.p34
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
clindamycin
|
magnesium
|
NONE
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p94
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
quetiapine
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p34
|
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.
|
barbiturates
|
tetracyclines
|
NONE
|
Norgestimate_ddi.xml
|
DDI-DrugBank.d360.s1
|
DDI-DrugBank.d360.s1.p6
|
Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
|
cefdinir
|
iron
|
MECHANISM
|
Cefdinir_ddi.xml
|
DDI-DrugBank.d420.s5
|
DDI-DrugBank.d420.s5.p12
|
The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.
|
INDOCIN
|
NSAIDs
|
ADVISE
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s4
|
DDI-DrugBank.d82.s4.p0
|
Therefore, 4 to 5 hours should elapse between administration of cholestyramine and thyroid hormones.
|
cholestyramine
|
thyroid hormones
|
ADVISE
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s10
|
DDI-DrugBank.d54.s10.p0
|
therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
|
lansoprazole
|
digoxin
|
MECHANISM
|
Lansoprazole_ddi.xml
|
DDI-DrugBank.d431.s12
|
DDI-DrugBank.d431.s12.p3
|
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.
|
dexamethasone
|
insulin
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s2
|
DDI-MedLine.d12.s2.p3
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
delavirdine
|
valproate
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p177
|
Specific drug interaction studies have not been performed with SUSTIVA and NRTIs other than lamivudine and zidovudine.
|
NRTIs
|
zidovudine
|
NONE
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s91
|
DDI-DrugBank.d531.s91.p4
|
Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.
|
ritonavir
|
VIRACEPT
|
MECHANISM
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s16
|
DDI-DrugBank.d340.s16.p4
|
In a single study, rats given high intraperitoneal doses of an MAO inhibitor plus disulfiram experienced severe toxicity, including convulsions and death.
|
MAO inhibitor
|
disulfiram
|
EFFECT
|
Isocarboxazid_ddi.xml
|
DDI-DrugBank.d108.s1
|
DDI-DrugBank.d108.s1.p0
|
- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);
|
Bactrim
|
Azulfidine
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s3
|
DDI-DrugBank.d521.s3.p17
|
in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.
|
terfenadine
|
dirithromycin
|
MECHANISM
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s5
|
DDI-DrugBank.d522.s5.p5
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
anticholinergic
|
antihistamines
|
EFFECT
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p8
|
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
|
intraconazole
|
budesonide
|
ADVISE
|
Budesonide_ddi.xml
|
DDI-DrugBank.d144.s1
|
DDI-DrugBank.d144.s1.p10
|
Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
|
antacids
|
norfloxacin
|
ADVISE
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s11
|
DDI-DrugBank.d217.s11.p16
|
In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.
|
fluoxetine
|
atomoxetine
|
MECHANISM
|
Atomoxetine_ddi.xml
|
DDI-DrugBank.d11.s4
|
DDI-DrugBank.d11.s4.p3
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
quinine
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p20
|
However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine.
|
escitalopram
|
desipramine
|
MECHANISM
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s32
|
DDI-DrugBank.d568.s32.p5
|
Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.
|
amphotericin B
|
flucytosine
|
EFFECT
|
Amphotericin B_ddi.xml
|
DDI-DrugBank.d318.s7
|
DDI-DrugBank.d318.s7.p2
|
In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (penicillins or cephalosporins) may result in a significant mutual inactivation.
|
aminoglycoside
|
antibiotics
|
EFFECT
|
Kanamycin_ddi.xml
|
DDI-DrugBank.d57.s0
|
DDI-DrugBank.d57.s0.p0
|
Drugs Decreasing Heparin Effect: Digitalis, tetracyclines, nicotine, or antihistamines may partially counteract the anticoagulant action of heparin sodium.
|
Digitalis
|
heparin sodium
|
EFFECT
|
Heparin_ddi.xml
|
DDI-DrugBank.d488.s6
|
DDI-DrugBank.d488.s6.p8
|
DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism.
|
Clarithromycin
|
simvastatin
|
MECHANISM
|
11197581.xml
|
DDI-MedLine.d25.s9
|
DDI-MedLine.d25.s9.p0
|
The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium.
|
gemifloxacin
|
aluminum
|
MECHANISM
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s6
|
DDI-DrugBank.d347.s6.p1
|
Warfarin: In a short-term controlled study in 14 normal volunteers, ketoprofen did not significantly interfere with the effect of warfarin on prothrombin time.
|
ketoprofen
|
warfarin
|
NONE
|
Ketoprofen_ddi.xml
|
DDI-DrugBank.d499.s15
|
DDI-DrugBank.d499.s15.p2
|
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.
|
glucocorticoids
|
PROLEUKIN
|
EFFECT
|
Aldesleukin_ddi.xml
|
DDI-DrugBank.d114.s10
|
DDI-DrugBank.d114.s10.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
amiodarone
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p3
|
It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram. since disulfiram may prolong prothrombin time.
|
anticoagulants
|
disulfiram
|
ADVISE
|
Disulfiram_ddi.xml
|
DDI-DrugBank.d19.s6
|
DDI-DrugBank.d19.s6.p0
|
Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker.
|
fentanyl
|
calcium channel blocker
|
EFFECT
|
Isradipine_ddi.xml
|
DDI-DrugBank.d81.s14
|
DDI-DrugBank.d81.s14.p4
|
Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.
|
Butyrophenones
|
dopamine
|
EFFECT
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s7
|
DDI-DrugBank.d325.s7.p2
|
On the contrary, neurotensin and tuftsin were agonists in induction of analgesia.
|
neurotensin
|
tuftsin
|
EFFECT
|
6545985.xml
|
DDI-MedLine.d131.s4
|
DDI-MedLine.d131.s4.p0
|
Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.
|
Rifampin
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s7
|
DDI-DrugBank.d450.s7.p0
|
It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.
|
buspirone HCl
|
psychotropic drugs
|
NONE
|
Buspirone_ddi.xml
|
DDI-DrugBank.d463.s0
|
DDI-DrugBank.d463.s0.p7
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
erythromycin
|
phenytoin
|
INT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p4
|
Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03).
|
atracurium
|
atracurium
|
NONE
|
8542840.xml
|
DDI-MedLine.d90.s7
|
DDI-MedLine.d90.s7.p0
|
If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.
|
phenytoin
|
Norpace
|
MECHANISM
|
Disopyramide_ddi.xml
|
DDI-DrugBank.d506.s0
|
DDI-DrugBank.d506.s0.p0
|
Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.
|
tolbutamide
|
Aprepitant
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s18
|
DDI-DrugBank.d382.s18.p9
|
Rifampin: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.
|
Rifampin
|
rifampin
|
NONE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s32
|
DDI-DrugBank.d340.s32.p0
|
Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure.
|
Sildenafil
|
short-acting nitrates
|
ADVISE
|
11213561.xml
|
DDI-MedLine.d1.s5
|
DDI-MedLine.d1.s5.p1
|
Antiretroviral Agents: No drug interactions with other antiretroviral medications have been identified that would warrant alteration of either the enfuvirtide dose or the dose of the other antiretroviral medication.
|
antiretroviral medications
|
antiretroviral medication
|
NONE
|
Enfuvirtide_ddi.xml
|
DDI-DrugBank.d535.s1
|
DDI-DrugBank.d535.s1.p4
|
Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.
|
EQUETROTM
|
alcohol
|
ADVISE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s18
|
DDI-DrugBank.d94.s18.p1
|
Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function.
|
nonsteroidal anti-inflammatory drugs
|
enalapril
|
EFFECT
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s4
|
DDI-DrugBank.d107.s4.p2
|
Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.
|
phenytoin
|
coumarin anticoagulants
|
MECHANISM
|
Ethotoin_ddi.xml
|
DDI-DrugBank.d359.s3
|
DDI-DrugBank.d359.s3.p1
|
In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.
|
bupropion
|
desipramine
|
MECHANISM
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s14
|
DDI-DrugBank.d5.s14.p0
|
Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
|
antipsychotics
|
antianxiety agents
|
NONE
|
Hydrocodone_ddi.xml
|
DDI-DrugBank.d396.s0
|
DDI-DrugBank.d396.s0.p6
|
Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.
|
TORADOL
|
anticoagulants
|
ADVISE
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s7
|
DDI-DrugBank.d3.s7.p9
|
The pressor effects of ERGOMAR and other vasoconstrictor drugs can combine to cause dangerous hypertension.
|
ERGOMAR
|
vasoconstrictor drugs
|
EFFECT
|
Ergotamine_ddi.xml
|
DDI-DrugBank.d59.s1
|
DDI-DrugBank.d59.s1.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
chlorpropamide
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p8
|
In combination with other central nervous system depressants, heroin may still kill even experienced users, particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased.
|
central nervous system depressants
|
heroin
|
EFFECT
|
Heroin_ddi.xml
|
DDI-DrugBank.d514.s1
|
DDI-DrugBank.d514.s1.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
oxyphenbutazone
|
triclofos sodium
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1310
|
The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.
|
alcohol
|
bromocriptine mesylate
|
EFFECT
|
Bromocriptine_ddi.xml
|
DDI-DrugBank.d272.s0
|
DDI-DrugBank.d272.s0.p2
|
Patients with major psychotic disorders, treated with neuroleptics, should be treated with dopamine agonists only if the potential benefits outweigh the risks.
|
neuroleptics
|
dopamine agonists
|
ADVISE
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s4
|
DDI-DrugBank.d357.s4.p0
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
acetaminophen
|
tranquilizers
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p13
|
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
|
Benzthiazide
|
Ibuprofen
|
INT
|
Benzthiazide_ddi.xml
|
DDI-DrugBank.d208.s0
|
DDI-DrugBank.d208.s0.p7
|
CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.
|
CANCIDAS
|
tacrolimus
|
MECHANISM
|
Caspofungin_ddi.xml
|
DDI-DrugBank.d350.s5
|
DDI-DrugBank.d350.s5.p0
|
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .
|
propafenone
|
carvedilol
|
EFFECT
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s1
|
DDI-DrugBank.d269.s1.p20
|
Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin
|
Antimycobacterial agents
|
rifabutin
|
NONE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s7
|
DDI-DrugBank.d340.s7.p2
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Sandimmune
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p22
|
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.
|
NSAIDs
|
furosemide
|
EFFECT
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s10
|
DDI-DrugBank.d328.s10.p3
|
Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge.
|
ethanol
|
disulfiram
|
EFFECT
|
6537219.xml
|
DDI-MedLine.d81.s2
|
DDI-MedLine.d81.s2.p0
|
The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
|
anticholinergics
|
tricyclic antidepressants
|
NONE
|
Glycopyrrolate_ddi.xml
|
DDI-DrugBank.d510.s0
|
DDI-DrugBank.d510.s0.p6
|
Aspirin: CELEBREX can be used with low dose aspirin.
|
CELEBREX
|
aspirin
|
ADVISE
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s13
|
DDI-DrugBank.d172.s13.p2
|
Isoflurane potentiates the muscle relaxant effect of all muscle relaxants, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.
|
Isoflurane
|
muscle relaxants
|
EFFECT
|
Isoflurane_ddi.xml
|
DDI-DrugBank.d227.s0
|
DDI-DrugBank.d227.s0.p0
|
Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, chlordiazepoxide, diazepam) and increase the clearance of others (lorazepam, oxazepam, temazepam).
|
hormonal contraceptives
|
lorazepam
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s17
|
DDI-DrugBank.d485.s17.p12
|
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of beta2-agonists.
|
diuretics
|
beta2-agonists.
|
EFFECT
|
Formoterol_ddi.xml
|
DDI-DrugBank.d103.s4
|
DDI-DrugBank.d103.s4.p20
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
cyclosporine
|
Agenerase
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p717
|
In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold diuretics during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.
|
diuretics
|
CAMPTOSAR
|
EFFECT
|
Irinotecan_ddi.xml
|
DDI-DrugBank.d279.s11
|
DDI-DrugBank.d279.s11.p2
|
Erythromycin (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.
|
Erythromycin
|
vardenafil
|
MECHANISM
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s5
|
DDI-DrugBank.d198.s5.p0
|
The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.
|
guanfacine
|
phenobarbital
|
MECHANISM
|
Guanfacine_ddi.xml
|
DDI-DrugBank.d507.s1
|
DDI-DrugBank.d507.s1.p0
|
Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.
|
paroxetine
|
aripiprazole
|
MECHANISM
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s8
|
DDI-DrugBank.d509.s8.p9
|
Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid, and tolbutamide in vitro .
|
propranolol
|
phenytoin
|
NONE
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s12
|
DDI-DrugBank.d460.s12.p10
|
Zalcitabine also has no significant effect on the intracellular phosphorylation of ZDV, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).
|
Zalcitabine
|
ZDV
|
EFFECT
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s1
|
DDI-DrugBank.d263.s1.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
quetiapine
|
triazolam
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p985
|
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.
|
hydralazine
|
digoxin
|
NONE
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s10
|
DDI-DrugBank.d107.s10.p34
|
Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.
|
antipsychotics
|
hydrocodone
|
EFFECT
|
Hydrocodone_ddi.xml
|
DDI-DrugBank.d396.s0
|
DDI-DrugBank.d396.s0.p9
|
Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.
|
TRICOR
|
bile acid binding resin
|
MECHANISM
|
Fenofibrate_ddi.xml
|
DDI-DrugBank.d283.s4
|
DDI-DrugBank.d283.s4.p5
|
Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, beta-blockers (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., diphenhydramine), any other drugs that may make you drowsy.
|
anti-depressants
|
sparfloxacin
|
NONE
|
Chlorpromazine_ddi.xml
|
DDI-DrugBank.d86.s1
|
DDI-DrugBank.d86.s1.p3
|
Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
|
erythromycin
|
bromocriptine
|
INT
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s24
|
DDI-DrugBank.d522.s24.p6
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
Probenecid
|
nonsteroidal anti-inflammatory
|
MECHANISM
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p26
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
caffeine
|
alcohol
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p18
|
However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.
|
caffeine
|
anticoagulant
|
NONE
|
Levofloxacin_ddi.xml
|
DDI-DrugBank.d242.s1
|
DDI-DrugBank.d242.s1.p9
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
disulfiram
|
sulindac
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p848
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
halothane
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p11
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
doxycycline
|
lorazepam
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p578
|
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.
|
zidovudine
|
zidovudine
|
NONE
|
11210404.xml
|
DDI-MedLine.d105.s7
|
DDI-MedLine.d105.s7.p4
|
Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..
|
epinephrine
|
halogenated hydrocarbon general anesthetics
|
EFFECT
|
Epinephrine_ddi.xml
|
DDI-DrugBank.d247.s5
|
DDI-DrugBank.d247.s5.p1
|
Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.
|
sympathomimetic agents
|
vasopressor
|
NONE
|
Linezolid_ddi.xml
|
DDI-DrugBank.d441.s2
|
DDI-DrugBank.d441.s2.p7
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
diazepam
|
itraconazole
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p514
|
Antacids: Concomitant administration of antacids containing magnesium or aluminum with VIDEX Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the antacid components.
|
magnesium
|
VIDEX
|
EFFECT
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s4
|
DDI-DrugBank.d43.s4.p10
|
No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.
|
sulfinpyrazone
|
contraceptives
|
NONE
|
Acebutolol_ddi.xml
|
DDI-DrugBank.d388.s5
|
DDI-DrugBank.d388.s5.p15
|
Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
|
paroxetine
|
5-HT1 agonists
|
EFFECT
|
Frovatriptan_ddi.xml
|
DDI-DrugBank.d426.s3
|
DDI-DrugBank.d426.s3.p19
|
Bentiromide may interact with acetaminophen (e.g., Tylenol), chloramphenicol (e.g., Chloromycetin), local anesthetics (e.g., benzocaine and lidocaine), para-aminobenzoic acid (PABA)-containing preparations (e.g., sunscreens and some multivitamins), procainamide (e.g., Pronestyl), sulfonamides (sulfa medicines), thiazide diuretics (use of these medicines during the test period will affect the test results), and pancreatic supplements (use of pancreatic supplements may give false test results).
|
Bentiromide
|
lidocaine
|
INT
|
Bentiromide_ddi.xml
|
DDI-DrugBank.d537.s0
|
DDI-DrugBank.d537.s0.p6
|
After the coadministration of 200 mg oral ketoconazole twice daily and one 20 mg dose of loratadine to 11 subjects, the AUC and Cmax of loratadine averaged 302% ( 142 S.D.) and 251% ( 68 S.D.), respectively, of those obtained after co-treatment with placebo.
|
ketoconazole
|
loratadine
|
MECHANISM
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s27
|
DDI-DrugBank.d458.s27.p0
|
Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.
|
thyroid
|
contraceptives
|
ADVISE
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s14
|
DDI-DrugBank.d54.s14.p2
|
Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.
|
itraconazole
|
clarithromycin
|
NONE
|
Eszopiclone_ddi.xml
|
DDI-DrugBank.d216.s9
|
DDI-DrugBank.d216.s9.p0
|
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
|
alprazolam
|
nifedipine
|
INT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s10
|
DDI-DrugBank.d131.s10.p10
|
Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.
|
Phenytoin
|
Phenobarbital
|
NONE
|
Cholecalciferol_ddi.xml
|
DDI-DrugBank.d404.s2
|
DDI-DrugBank.d404.s2.p0
|
Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
|
non-steroidal anti-inflammatory agent
|
potassium-sparing diuretics
|
EFFECT
|
Hydrochlorothiazide_ddi.xml
|
DDI-DrugBank.d162.s12
|
DDI-DrugBank.d162.s12.p5
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.